CHORD - CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Brief description of study

The purpose of this study is to investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke. In this study, we will investigate risk factors for heart disease and stroke, including platelet (involved in clotting) activity, inflammation, blood vessel wall function, and genetic information (blueprints of your cells). Participants with type 2 diabetes and elevated cholesterol will receive cholesterol lowering medicines (PCSK9 inhibitor plus statin or ezetimibe) which are therapies designed to prevent heart disease. The study will compare their risk factors before and after cholesterol reduction, and also with healthy control patients with elevated cholesterol who do not have diabetes. The control group will also receive the same cholesterol lowering medicines.

Clinical Study Identifier: s19-01964 Identifier: NCT04369664

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.